Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 20 Neoplasms 4 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thoracic Neoplasms 1 Solid Tumors 1 Sarcoma 1 Salivary Gland Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms, Unknown Primary 1 Neoplasms by Site 1 Multiple Endocrine Neoplasia Type 2a 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Neoplasms 1 Lung Diseases 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Colonic Diseases 1

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × ALK+ Advanced NSCLC × alectinib × Clear all

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡